Literature DB >> 6285812

Treatment of infections caused by ampicillin-resistant pathogens with a combination of ampicillin and CP-45,899.

J F Plouffe.   

Abstract

Eleven patients infected with ampicillin-resistant organisms were treated with a combination of CP-45,899, a beta-lactamase inhibitor, and ampicillin. All infections were controlled within 7 days without any signs of toxicity.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6285812      PMCID： PMC181928          DOI： 10.1128/AAC.21.3.519

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  3 in total

1.  Interaction of clindamycin and gentamicin in vitro.

Authors:  R J Fass; C A Rotilie; R B Prior
Journal:  Antimicrob Agents Chemother       Date:  1974-11       Impact factor: 5.191

2.  Comparative inhibition beta-lactamases by novel beta-lactam compounds.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

3.  CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides.

Authors:  J A Retsema; A R English; A E Girard
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191
  3 in total
  4 in total

Review 1.  Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.

Authors:  D M Campoli-Richards; R N Brogden
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

2.  Pharmacokinetic and therapeutic trial of sultamicillin in acute sinusitis.

Authors:  S Jones; V L Yu; J T Johnson; R L Wagner; H K Kim
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

3.  In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria.

Authors:  H M Wexler; B Harris; W T Carter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

4.  Clinical and pathological evaluation of sulbactam/ampicillin for treatment of experimental bovine pneumonic pasteurellosis.

Authors:  G A Gifford; A A Potter; L A Babiuk
Journal:  Can Vet J       Date:  1988-02       Impact factor: 1.008
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.